Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

<div>Trial profile. DOX = capecitabine, oxaliplatin, and docetaxel; XELOX = capecitabine and oxaliplatin.</div>

Gastroenterology Research and Practice

fig1

Figure 1

Figure 1: Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma 

Figure 1 | Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma 